If you're a biotech employee holding employer stock through years of clinical development, waiting for an FDA approval to make your next move, you're not alone. When the outcome is binary and the financial stakes are material, that combination warrants careful planning.
How should biotech employees manage equity risk before an FDA decision?
Maximizing an Outcome You Can't Control
People who attempt to maximize their outcome by waiting for an FDA decision succeed more often than some might think. Unfortunately, maximization occurs in both directions.
The goal of capturing the best possible result is understandable — it's how most financial decisions should work. But that assumes a range of outcomes where patience and judgment can tilt the odds. Binary events don't work that way. Waiting to maximize doesn't improve your position. It concentrates your exposure to a single moment you don't control, decided by an agency that has no obligation to consider your timeline, your liquidity needs, or your household's financial situation.
Most people wouldn't willingly place material control of their financial life in the hands of a government agency. Yet when an FDA decision determines whether your stock retains its value, that's precisely the position you're in. The question isn't whether you trust the science. It's whether you've made a deliberate choice about how much of your financial security hinges on that decision — and whether there's still time to make one.
FDA Approval Is Not a Guarantee
For those approaching an FDA readout, the approval process is reliably unpredictable. Late-stage trials can fail, even when the science seems strong. The FDA's decision isn't just about the data; it's about meeting stringent regulatory standards. You might be confident in your company's research, but that doesn't guarantee approval from a government body whose purpose is to manage risk. The reality is that many promising drugs don't make it through the final hurdle. If your financial plan hinges on approval, you're betting on an outcome you can't control.
Approval Doesn't Mean Immediate Gains
Even if approval comes, it doesn't always translate to immediate financial gain. Stock prices may have already factored in a favorable outcome, limiting the potential upside. Early investors might sell, creating downward pressure on the stock. And potential secondary share offerings can dilute your gains. Good news doesn't automatically mean liquidity on your timeline or at your desired price.
Trading Windows May Not Align with Personal Plans
A common assumption is that the trading window will be open post-approval. Unfortunately, this isn't always the case. The announcement itself is a material event that can trigger blackout restrictions for insiders. You might find that the last clean opportunity to act was before the announcement, not after. The window you were counting on might close just when you need it most, leaving you with fewer options than anticipated.
A Financial Plan Shouldn't Rely on a Single Outcome
If your financial plan depends on one specific outcome, it's not a plan — it's a gamble. Households that navigate these binary events successfully are those that define in advance how much of their financial security they're willing to expose to a single result. This often means harvesting gains at opportune times, rather than trying to perfectly time an unpredictable event. It's about making deliberate choices when the window is open, not scrambling after the fact.
Pro-Tip
The question to ask before a major FDA readout is not whether the drug will be approved. It is whether your household's financial situation changes materially depending on the answer — and if so, whether that exposure was chosen deliberately or has not been directly addressed. Having a financial plan in place enables you to consider how selling your shares can permanently improve your current financial situation, in a material way, at times when you are able to trade your shares.
If you'd like to explore whether ongoing financial planning and investment management make sense for your situation, you can schedule an intro call here:
Common Questions
Why does a clinical stage biotech go public?
Clinical stage biotechs go public to raise capital needed for expensive drug development and trials. Going public provides access to a larger pool of investors and the funds necessary to bring a drug to market. The eventual binary outcome means that when funding needs become large, and the science is early but looks promising, private market investors avoid taking large stakes in individual companies to diversify their positions.
What typically happens to a biotech stock price after FDA approval?
After FDA approval, a biotech's stock price can be volatile. While approval is positive news, the stock may have already priced in the outcome, and selling pressure from early investors can affect the price. Market dynamics post-approval can be unpredictable. Employees find themselves greatly affected, but lack control over the situation, or even trading their shares if they are in a blackout period.
Why do biotech employees sometimes miss the window to sell after good trial results?
Biotech employees may miss the window to sell due to blackout periods triggered by material events like trial results. These restrictions can prevent insiders from selling, and the anticipated trading window may not align with these regulatory constraints.